Mandala Intervention on Mental Distress in Nurses Working With Terminally Ill Patients (mandala)
Mandala Intervention on Mental Health Problems of Nurses Caring for Terminally Ill Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
İSTANBUL/halkalı
-
Istanbul, İSTANBUL/halkalı, Turkey, 34000
- SZU
-
-
İ̇stanbul
-
Istanbul, İ̇stanbul, Turkey, 34000
- SZU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
volunteer
- active employee
- year of study
Exclusion Criteria:
- paint allergy
- use of psychiatric drugs Loss of loved one in the last six months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: mental health
The effect of mandala painting on mental health.
Mental health-related anxiety, depression, well-being, distress and death anxiety and depression will be measured.
|
nurse painted mandala for relaksing
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Beck depresion scale
Time Frame: 4 week
|
depresion is mental breakdown, depresion for beck depresion scale, 0-9 depresion emity, 10-15 light depression, 16-23 middle depresion, 24- 63 severe depression
|
4 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
STAI-trait anxiety scale
Time Frame: 4 week
|
anxiete is boredom, anxiete for trait anxiety scale, 0-15 anxiety none,n , 15-30 light anxiety, 30-60 middle anxiety, over 60 severe anxiety
|
4 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: RUKİYE PINAR BÖLÜKTAŞ, SZU
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- ISZU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.